Discover the crucial information about Feline Hypertrophic Cardiomyopathy (FHC), a prevalent heart disease affecting 10-15% of domestic cats, particularly Maine Coon and Ragdoll breeds. Learn about its causes, symptoms, diagnosis, and management strategies, including the role of genetic mutations, cardiac biomarkers, and medications like beta-blockers and calcium channel blockers. Understand how early diagnosis and adapted management can help mitigate serious complications such as heart failure and sudden death.
Extract
[...] 11] This mutation disrupts the myosin's ability to interact with actin and can thus disrupt systolic and diastolic functions. A poor heart contraction leads to thickening of the walls to try to compensate for this abnormal contractility. 2. Tools for establishing a diagnosis in cellular biology The clinical symptoms of feline CMH are often subtle, making diagnosis difficult. There are also cases of subclinical CMH where no symptoms are observable. In order to make a diagnosis, veterinarians will rely on a set of observations from physical examinations (cardiac auscultation) and medical imaging such as echocardiography, which will allow visualization of ventricular hypertrophy and also enable observation of cardiac function. [...]
[...] Hypertrophic cardiomyopathy in young Maine Coon cats caused by the p.A31P cMyBP-C mutation - the clinical significance of having the mutation. Acta Vet Scand. 2011; 53(1):7. 10. Kittleson Meurs Harris S. The genetic basis of hypertrophic cardiomyopathy in cats and humans. J Vet Cardiol. 2015; 17: S53-S73. 11. Meurs Sanchez David Bowles Towbin Reiser Kittleson Munro Dryburgh MacDonald Kittleson A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy. Hum Mol Genet. 2005; 14:3587-3593. 12. [...]
[...] The causes of feline hypertrophic cardiomyopathy are varied. In many cases, the disease is idiopathic, meaning that no specific cause is identified. However, genetic factors play a significant role, particularly in certain breeds, such as the Maine Coon and the Ragdoll, where specific mutations have been identified on the MyBPC3 gene. These mutations lead to dysfunction of the contractile units (sarcomeres) and therefore to poor cardiac contraction. Furthermore, CMH may result from other pathologies, such as hyperthyroidism, hypertension, or metabolic diseases. [...]
[...] - Calcium channel blockers : Diltiazem, a calcium channel blocker, is sometimes prescribed to improve heart muscle relaxation and thus reduce the stiffness of the heart walls. - Anticoagulants : In advanced cases of CMH, there is an increased risk of blood clot formation (thrombo-embolism), particularly in the aorta. Anticoagulants are therefore administered to prevent these serious complications. - Diuretics : If the cat shows signs of heart failure, such as fluid accumulation in the lungs (pulmonary edema), diuretics are used to reduce this excess fluid and relieve breathing. Conclusion Feline Hypertrophic Cardiomyopathy (FHC) is the most common heart disease in cats. [...]
[...] In summary, feline hypertrophic cardiomyopathy is a complex heart disease that requires early diagnosis and adapted management. This pathology is not exclusive to cats, it is also found in humans and this is why it is studied so much because even if the mutations involved are not exactly the same as in humans, the cat represents an animal model of this disease and allows us to better understand the mechanisms at play. Bibliography 1. Kittleson M & Côté E. The Feline Cardiomyopathies: 2. [...]
